First pill for obstructive sleep apnea could reach market in 2027
Apnimed plans an FDA filing for a nightly pill that reduced sleep-apnea severity in phase 3 trials. The oral treatment could offer an alternative to CPAP for millions.
Copy link
By Torontoer Staff
Apnimed, a Cambridge, Massachusetts, biotech, is preparing an FDA submission for the first pill designed to treat obstructive sleep apnea. If regulators agree, the drug could be available in the first half of 2027, providing an alternative to continuous positive airway pressure machines for many patients.
Obstructive sleep apnea affects an estimated 80 million people in the United States. Current standard care relies on CPAP devices that keep the airway open with pressurised air, a method that works clinically but is widely disliked and often abandoned. A tolerable oral treatment would change how the condition is managed for a large group of patients.
How the pill works
The medication combines two existing drugs to target the brain stem mechanisms that permit airway collapse during sleep. In simplified terms, it keeps throat muscles from fully relaxing while allowing the brain to sleep. Developers describe the approach as restoring the balance between muscle tone and sleep state to prevent breathing pauses.
It was like, 'Wow, I can't believe my eyes,'
Dr. Luigi Taranto Montemurro, cofounder and chief scientific officer, on the first successful patient observation
Clinical evidence so far
Apnimed completed phase 3 studies that showed a meaningful reduction in the apnea-hypopnea index, a standard measure of sleep-apnea severity. In one trial reported in 2024 the drug reduced that index by 47 percent at 26 weeks, compared with 7 percent for placebo. The company reported no serious adverse events; common side effects included dry mouth and insomnia.
The data position the pill as a direct treatment for airway collapse during sleep, distinct from weight-loss medications that can improve sleep apnea indirectly by reducing body weight. The FDA recently approved a weight-loss drug for sleep apnea in people with obesity, but that treatment is not a direct pharmacological therapy for the condition itself.
Funding, valuation and commercial plans
Apnimed has raised about $260 million from investors including Morningside, Alpha Wave Global and Sectoral Asset Management, valuing the company at roughly $400 million. The firm has no commercial revenue yet and is exploring options to fund a launch, including an initial public offering.
Co-founder and CEO Dr. Larry Miller, a pulmonary specialist, said the company expects demand to be substantial if the drug reaches the market. He noted that even modest adoption rates would put the drug in blockbuster territory given the size of the undiagnosed and untreated population.
The numbers are staggering. I think people will be using it in the millions.
Dr. Larry Miller, cofounder and CEO, Apnimed
Why many people do not use CPAP
CPAP is effective, but many patients reject it because of discomfort, noise and lifestyle disruption. Surveys and clinical experience suggest a substantial portion of diagnosed patients either never start CPAP or discontinue it. That gap between diagnosis and effective treatment is a central commercial and public-health opportunity for a pill-based therapy.
Broader implications for patients and health systems
Untreated sleep apnea contributes to higher risks of cardiovascular disease, stroke and other long-term conditions. Clinicians and investors who consulted with Apnimed framed a successful oral therapy as potentially transformative because it could improve adherence and reach patients who avoid CPAP.
Obstructive sleep apnea is a massive public health problem that is underrecognized, undertreated and underdiagnosed.
Dr. Nate Watson, sleep medicine specialist and former president of the American Academy of Sleep Medicine
Apnimed is already in discussions with insurers about coverage, which will be key to uptake. The company is also developing additional molecules in partnership with Japanese firm Shionogi to expand treatment options.
What to watch next
The next milestones are the FDA filing and regulatory review. Approval would lead to commercial launch planning, supply scaling and payer negotiations. Clinicians will watch longer-term safety and real-world adherence data to understand how the pill compares to device therapy across different patient groups.
For people living with sleep apnea, an effective oral therapy would broaden choices and could increase the proportion who receive treatment. For the health system, wider treatment uptake could reduce downstream complications linked to untreated sleep-disordered breathing.
Apnimed's timeline depends on regulators, but if the company secures approval and reimbursement, a pill for sleep apnea could change standard care from a device-first model to one that includes pharmacological options.
sleep apneahealthbiotechApnimedFDACPAP
